Delaware Court Consolidates, Postpones Trial In Adderall XR Patent Challenge

Law360, New York (April 15, 2005, 12:00 AM EDT) -- A Delaware federal court has postponed the trial in Impax Laboratories, Inc.’s patent challenge against Shire Pharmaceuticals Group’s best-selling attention-deficit-disorder treatment Adderall XR until February 2006.

Shire has two pending suits against Impax based on the generics maker’s plans to make 5 mg, 10 mg, 15 mg, 20 mg, 25 mg and 30 mg generic versions of Adderall XR.

Impax sent Shire two separate notices that it would be challenging the validity of the main ingredients in the drug, prompting two separate lawsuits for different dosages....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.